Chinook therapeutics revenue
WebApr 10, 2024 · An auction of Pear’s assets is expected to happen in early May. Pear Therapeutics’ search for a buyer has yet to lead to a consummated deal, and the beleaguered digital therapeutics company is ... WebFeb 27, 2024 · The higher revenue amounts in 2024 were primarily due to $41.2 million non-cash revenue recognized under Chinook’s license agreement with SanReno Therapeutics and a $10.0 million milestone ...
Chinook therapeutics revenue
Did you know?
WebMar 25, 2024 · This is a summary of current ratings and price targets for Bio-Path and Chinook Therapeutics, as provided by MarketBeat. Bio-Path presently has a consensus price target of $9.00, indicating a ... WebFeb 26, 2024 · Based on Chinook Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.5 million and a GAAP net loss of $55.98 million.
WebSep 30, 2024 · SEATTLE, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the third quarter ended September 30, … WebChinook Therapeutics revenue from 2014 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of …
WebNov 8, 2024 · Chinook (KDNY) delivered earnings and revenue surprises of 17.07% and -98.40%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? WebApr 13, 2024 · Chinook Therapeutics, Inc. SEATTLE, April 13, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and ...
WebFeb 24, 2024 · Chinook Therapeutics is a biotechnology company developing precision medicines for kidney diseases. The company applies its proprietary discovery platform, which leverages single-cell RNA sequencing, human-derived organoids, and new translational models, to discover and develop therapeutics with novel mechanisms of …
WebApr 13, 2024 · Chinook Therapeutics, Inc. SEATTLE, April 13, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical … cy hop-o\u0027-my-thumbWebChinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases. Changing the Course of Kidney Care™ Read More cy hornet\u0027sWebFeb 25, 2024 · Chinook is headquartered in Berkeley, California, the US. The company reported revenues of (US Dollars) US$51.6 million for the fiscal year ended December 2024 (FY2024), compared to a revenue of US$0.8 million in FY2024. The operating loss of the company was US$99 million in FY2024, compared to an operating loss of US$83.9 … cy hope sleeper sofasWebApr 6, 2024 · 9 brokers have issued 1 year price objectives for Chinook Therapeutics' shares. Their KDNY share price forecasts range from $30.00 to $44.00. On average, they predict the company's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 64.1% from the stock's current price. cy hopper\u0027sWebFeb 27, 2024 · Chinook Therapeutics (KDNY) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to earnings of $0.14 per share a year ago. These ... cy hormone\u0027sWebAndrew is chief scientific officer at Chinook Therapeutics, overseeing the discovery research, non-clinical development and translational medicine teams. Andrew joined … cyhour6#outlook.comWebJun 2, 2024 · Conference Call Details. Chinook and Aduro will host a live conference call and webcast on Tuesday, June 2, 2024, at 8:30 am EDT to discuss the proposed transaction. To access the call, please ... cyhou